All Insights Report Real-World Evidence Usage in Regulatory Approvals from USFDA and EMA

    Real-World Evidence Usage in Regulatory Approvals from USFDA and EMA

    Real-World Evidence

    Real-World Evidence Usage in Regulatory Approvals from USFDA and EMA

    Study Report

    Download Report
    Real-World Evidence Usage in Regulatory Approvals from USFDA and EMA

     

    Real-world evidence (RWE) studies can be used at all stages of the product lifecycle and can provide information that complements randomized controlled trials (RCTs) to support clinical, regulatory, and reimbursement decisions. RWE is becoming a part of integrated evidence generation and creating continuity from premarket to iterative post-market approval decisions. The acceptance of RWE for regulatory approval differs across countries. This study identifies and compares the inclusion of RWE as part of an evidence package to support approvals by the United States Food and Drug Administration (USFDA) & European Medicines Agency (EMA).

    Contact us at insights@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    RWE Usages in USFDA & EMA Regulatory Approvals Report

    Report

    Risk Of Venous Thromboembolism And Major Bleeding In Patients With Acute Medical Illness Receiving Thromboprophylaxis With Enoxaparin

    RWE Usages in USFDA & EMA Regulatory Approvals Report

    Blog

    Unveiling the Key Trends and Topics: Axtria's Insights from ISPOR 2023

    RWE Usages in USFDA & EMA Regulatory Approvals Report

    Report

    The Potential Of Real-World Evidence To Complement Basket Trials For Tissue-Agnostic Drugs Targeting Neurotrophic Tropomyosin-Related Kinase Gene Fusions